Tracon files for IPO

Tracon Pharmaceuticals Inc. (San Diego, Calif.) filed to raise up to $57.5 million in an IPO on NASDAQ underwritten by Wells Fargo; Stifel; Needham; and Oppenheimer.

Tracon expects data in late 2015 to mid-2016 from four Phase II combination trials of lead program IV TRC105 to treat various cancers, including advanced soft tissue sarcoma, metastatic and advanced renal cell carcinoma (RCC), and glioblastoma multiforme (GBM). It intends to start at least one Phase III trial of the human chimeric mAb against endoglin ( CD105; ENG) by YE16. ...